FR2936711A1 - Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge - Google Patents
Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge Download PDFInfo
- Publication number
- FR2936711A1 FR2936711A1 FR0805509A FR0805509A FR2936711A1 FR 2936711 A1 FR2936711 A1 FR 2936711A1 FR 0805509 A FR0805509 A FR 0805509A FR 0805509 A FR0805509 A FR 0805509A FR 2936711 A1 FR2936711 A1 FR 2936711A1
- Authority
- FR
- France
- Prior art keywords
- orally administrable
- composition according
- administrable composition
- combination
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 239000000284 extract Substances 0.000 title claims abstract description 18
- 244000019459 Cynara cardunculus Species 0.000 title claims abstract description 14
- 235000019106 Cynara scolymus Nutrition 0.000 title claims abstract description 14
- 235000016520 artichoke thistle Nutrition 0.000 title claims abstract description 14
- 239000003524 antilipemic agent Substances 0.000 title claims abstract description 13
- 229940026314 red yeast rice Drugs 0.000 title claims abstract description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims description 8
- 235000015872 dietary supplement Nutrition 0.000 title claims description 7
- 230000002265 prevention Effects 0.000 title claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 240000007594 Oryza sativa Species 0.000 claims description 14
- 235000007164 Oryza sativa Nutrition 0.000 claims description 14
- 235000007189 Oryza longistaminata Nutrition 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 239000006000 Garlic extract Substances 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000020706 garlic extract Nutrition 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- 229930003935 flavonoid Natural products 0.000 claims description 6
- 235000017173 flavonoids Nutrition 0.000 claims description 6
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 claims description 6
- 240000002234 Allium sativum Species 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 150000002215 flavonoids Chemical class 0.000 claims description 5
- 235000004611 garlic Nutrition 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 4
- 240000000111 Saccharum officinarum Species 0.000 claims description 4
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 4
- 229930003537 Vitamin B3 Natural products 0.000 claims description 4
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000010081 allicin Nutrition 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 235000010204 pine bark Nutrition 0.000 claims description 4
- 235000019160 vitamin B3 Nutrition 0.000 claims description 4
- 239000011708 vitamin B3 Substances 0.000 claims description 4
- 229960002666 1-octacosanol Drugs 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 229940057070 sugarcane extract Drugs 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000003014 reinforcing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 230000002402 anti-lipaemic effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 38
- 235000012000 cholesterol Nutrition 0.000 description 18
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 238000008214 LDL Cholesterol Methods 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 244000113306 Monascus purpureus Species 0.000 description 2
- 235000002322 Monascus purpureus Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940057059 monascus purpureus Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000008428 ajoenes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000026776 severe myalgia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (11)
- REVENDICATIONS1. Composition administrable par voie orale, caractérisée en ce qu'elle comprend une association d'agents 5 hypolipidémiants incluant au moins un extrait sec de feuilles d'artichaut et de la levure de riz rouge.
- 2. Composition administrable par voie orale selon la revendication 1, caractérisée en ce que l'extrait sec de feuille d'artichaut contient au moins 4 io %, de préférence entre 5 et 6 % en poids, d'acide cafféolylquinique et la levure de riz rouge au moins 0,2 % en poids de monacoline, de préférence au moins 0,4 %.
- 3. Composition administrable par voie orale selon l'une des revendications 1 15 et2, caractérisée en ce que ladite association d'agents hypolipidémiants comprend en outre des polycosanols.
- 4. Composition administrable par voie orale selon la revendication 3, 20 caractérisée en ce que lesdits polycosanols sont formés par un extrait de canne à sucre contenant au moins 60 % d'octacosanol.
- 5. Composition administrable par voie orale selon l'une des revendications 1 à 4, 25 caractérisée en ce que ladite association d'agents hypolipidémiants comprend en outre un extrait d'ail renforçant l'action de la levure de riz rouge, ledit extrait d'ail contenant de préférence au moins 0,5 % d'allicine et 1,5 0/0 d'alliine. 30
- 6. Composition administrable par voie orale selon l'une des revendications 1 à 5, caractérisée en ce qu'elle contient, en sus de l'association d'agents hypolipidémiants, au moins deux agents antioxydants, l'un comprenant de lavitamine E, l'autre ou un autre des flavonoïdes, de préférence de la famille des oligomères proanthocyanidiques.
- 7. Composition administrable par voie orale selon l'une des revendications 1 5 à 6, caractérisée en ce qu'elle comprend en outre de la vitamine B2 et de la vitamine B3.
- 8. Composition administrable par voie orale selon l'une des revendications 1 ~o à 7, caractérisée en ce qu'elle se présente sous forme de comprimés, pelliculés ou non, ou de gélules ou de capsules, l'extrait sec de feuilles d'artichauts et la levure de riz rouge représentant au moins 30 %, de préférence 30 à 50 % en poids du comprimé ou de la gélule ou de la capsule. 15
- 9. Composition administrable par voie orale selon l'une des revendications 1 à 8, caractérisée en ce qu'elle comprend, exprimés en pourcentage en poids, rapporté au poids total de la composition, au moins 20 %, de préférence 20 entre 23 et 35 %, d'extrait sec de feuilles d'artichaut, 15 %, de préférence entre 20 et 30 % de levure de riz rouge, 0,8 %, de préférence entre 1 et 5 % de vitamine E, 0,5 %, de préférence entre 1 et 10 % d'extrait d'ail, 0,5 %, de préférence entre 0,7 et 3 % d'oligomères-proanthocyanidiques d'écorce de pin, 0,2 %, de préférence entre 0,4 et 3 % de polycosanols de canne à sucre. 25
- 10. Composition administrable par voie orale selon l'une des revendications 1 à 9 pour son application dans la prévention et/ou l'aide au traitement de l'hypercholestérolémie. 30
- 11. Complément alimentaire, caractérisé en ce qu'il comprend une composition administrable par voie orale selon l'une des revendications 1 à 9.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0805509A FR2936711B1 (fr) | 2008-10-06 | 2008-10-06 | Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0805509A FR2936711B1 (fr) | 2008-10-06 | 2008-10-06 | Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2936711A1 true FR2936711A1 (fr) | 2010-04-09 |
FR2936711B1 FR2936711B1 (fr) | 2012-09-21 |
Family
ID=40591997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR0805509A Active FR2936711B1 (fr) | 2008-10-06 | 2008-10-06 | Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR2936711B1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPI20110038A1 (it) * | 2011-04-08 | 2012-10-09 | Funcional Food Res S R L | Composizione alimentare funzionale a base di farina. |
WO2013063533A1 (fr) * | 2011-10-26 | 2013-05-02 | Clinical And Herbal Innovations, Inc. | Complément alimentaire pour la santé vasculaire |
EP2719288A1 (fr) | 2012-10-12 | 2014-04-16 | Ion Gigel Fulga | Composition pour le traitement ou la prévention de dyslipidémies |
WO2014104884A1 (fr) * | 2012-12-27 | 2014-07-03 | Leendert Taal | Préparation médicale destinée à traiter l'hypercholestérolémie |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999023996A2 (fr) * | 1997-11-06 | 1999-05-20 | Peking University | Compositions contenant des produits fermentes a base de riz rouge et procedes associes |
WO2003013562A1 (fr) * | 2001-08-08 | 2003-02-20 | Lichtwer Pharma Ag | Extraits de feuilles d'artichaut |
KR20040052904A (ko) * | 2004-05-13 | 2004-06-23 | 약초나라(주) | 혈중 콜레스테롤 및 중성지방 농도 저하 기능을 가지는천연물 조성물 및 그 제품 |
US20050220868A1 (en) * | 2004-03-31 | 2005-10-06 | Marcor Development Corporation | Policosanol composition and its use in treatment of hypercholesterolemia |
US20070160695A1 (en) * | 2006-01-09 | 2007-07-12 | Clouatre Dallas L | Pharmaceutical preparations for treating hypertension and dyslipidemia with Allium ursinum and Allium sativum |
EP1967199A1 (fr) * | 2007-03-07 | 2008-09-10 | Indena S.P.A. | Extraits de cynara scolymus et compositions les contenant |
-
2008
- 2008-10-06 FR FR0805509A patent/FR2936711B1/fr active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999023996A2 (fr) * | 1997-11-06 | 1999-05-20 | Peking University | Compositions contenant des produits fermentes a base de riz rouge et procedes associes |
WO2003013562A1 (fr) * | 2001-08-08 | 2003-02-20 | Lichtwer Pharma Ag | Extraits de feuilles d'artichaut |
US20050220868A1 (en) * | 2004-03-31 | 2005-10-06 | Marcor Development Corporation | Policosanol composition and its use in treatment of hypercholesterolemia |
KR20040052904A (ko) * | 2004-05-13 | 2004-06-23 | 약초나라(주) | 혈중 콜레스테롤 및 중성지방 농도 저하 기능을 가지는천연물 조성물 및 그 제품 |
US20070160695A1 (en) * | 2006-01-09 | 2007-07-12 | Clouatre Dallas L | Pharmaceutical preparations for treating hypertension and dyslipidemia with Allium ursinum and Allium sativum |
EP1967199A1 (fr) * | 2007-03-07 | 2008-09-10 | Indena S.P.A. | Extraits de cynara scolymus et compositions les contenant |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Week 200470, Derwent World Patents Index; AN 2004-716600 * |
HEBER DAVID ET AL: "Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 69, no. 2, February 1999 (1999-02-01), pages 231 - 236, XP002527519, ISSN: 0002-9165 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITPI20110038A1 (it) * | 2011-04-08 | 2012-10-09 | Funcional Food Res S R L | Composizione alimentare funzionale a base di farina. |
WO2012137163A1 (fr) * | 2011-04-08 | 2012-10-11 | Funcional Food Research S.R.L. | Aliment fonctionnel à base de farine |
WO2013063533A1 (fr) * | 2011-10-26 | 2013-05-02 | Clinical And Herbal Innovations, Inc. | Complément alimentaire pour la santé vasculaire |
EP2719288A1 (fr) | 2012-10-12 | 2014-04-16 | Ion Gigel Fulga | Composition pour le traitement ou la prévention de dyslipidémies |
WO2014104884A1 (fr) * | 2012-12-27 | 2014-07-03 | Leendert Taal | Préparation médicale destinée à traiter l'hypercholestérolémie |
US9655942B2 (en) | 2012-12-27 | 2017-05-23 | Leendert Taal | Medical formulation for treating hypercholesterolemia |
AU2013368749B2 (en) * | 2012-12-27 | 2018-04-05 | Anita Monique Taal-Vlas | Medical formulation for treating hypercholesterolemia |
EP3536331A1 (fr) * | 2012-12-27 | 2019-09-11 | Taal-Vlas, Anita Monique | Formulation médicale pour le traitement de l'hypercholestérolémie |
Also Published As
Publication number | Publication date |
---|---|
FR2936711B1 (fr) | 2012-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2606874B1 (fr) | Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications | |
KR102211814B1 (ko) | 대사 증후군의 치료를 위한 시나라 스콜리무스, 코페아 속, 및 올레아 유로파에아의 신규한 추출물 | |
CA2696207A1 (fr) | Fraction d'extrait de feuille de melisse presentant des activites inhibitrices d'angiogenese et de mmp, et composition en comportant | |
KR20190135497A (ko) | 시나라 카르둔큘러스 및 시트러스 아우란티움 베르가미아의 추출물, 이들의 조합물, 및 이들을 함유하는 제제 | |
FR2936711A1 (fr) | Composition orale, en particulier complement alimentaire comprenant un extrait sec de feuilles d'artichaut et de la levure de riz rouge | |
KR102337965B1 (ko) | 레몬 과피 추출물과 고삼 뿌리 추출물을 이용한 항염증용 조성물 | |
WO2004023897A1 (fr) | Composition comprenant en association au moins une huile de courge et au moins une huile de bourrache, son utilisation comme medicament, comme agent dermatologique ou dermato-cosmetique | |
EP2397136B1 (fr) | Composition anti-inflammatoire | |
CA2697125A1 (fr) | Utilisation d'au moins un derive oxime de la cholest-4-en-3-one comme antioxydants | |
US20070009618A1 (en) | Composition for preventing atherosclerosis | |
EP3182966B1 (fr) | Composition pour la prévention et le traitement de troubles métaboliques associés à la ménopause et au climatère | |
WO2006042928A1 (fr) | Composition pour prevenir ou traiter le stress, notamment les bouffees de stress chronique et permanent | |
EP3624822B1 (fr) | Principe actif constitue par un melange de composes poly-lysine et utilisation dans la prevention des avc et le traitement de la phase inflammatoire post-avc | |
KR102035281B1 (ko) | 말굽버섯의 에틸아세테이트 추출물을 포함하는 혈관 이완용 조성물 | |
FR2733418A1 (fr) | Nouvelles associations comprenant du (-) hydroxycitrate et presentant notamment de nouvelles activites therapeutiques | |
WO2020225319A1 (fr) | Extrait d'aigremoine comme agent anti-pollution | |
JP2004137218A (ja) | 脂肪分解促進剤ならびにそれを用いた皮膚外用剤および飲食物 | |
FR2991181A1 (fr) | Composition pharmaceutique ou dietetique pour inhiber l'absorption intestinale du sucre et utilisable pour soigner le syndrome metabolique | |
WO2007003762A1 (fr) | Complément alimentaire et son utilisation pour la prévention ou la lutte contre les effets des affections articulaires | |
Janvier et al. | The potential effect of aqueous extract of detarium microcarpum bark on certain metabolic disorders associated with an atherogenic diet in rats | |
EP2460518A1 (fr) | Composition comprenant un élément chondroprotecteur et des vitamines | |
EP0519777A1 (fr) | Formes galeniques à base de plantes fraiches ou sèches | |
BE1026487B1 (fr) | Composition comprenant au moins un extrait végétal | |
LU100019B1 (fr) | Composition destinée à être utilisée dans le traitement du psoriasis | |
BE1024512B1 (fr) | Composition destinée à être utilisée dans le traitement du Psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TP | Transmission of property |
Owner name: SEMREH EUROPE, LU Effective date: 20141029 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
PLFP | Fee payment |
Year of fee payment: 10 |
|
TP | Transmission of property |
Owner name: SEMREH EUROPE, LU Effective date: 20170522 |
|
PLFP | Fee payment |
Year of fee payment: 11 |
|
PLFP | Fee payment |
Year of fee payment: 13 |
|
CA | Change of address |
Effective date: 20200907 |
|
PLFP | Fee payment |
Year of fee payment: 14 |
|
PLFP | Fee payment |
Year of fee payment: 15 |
|
PLFP | Fee payment |
Year of fee payment: 16 |
|
PLFP | Fee payment |
Year of fee payment: 17 |